MX2015011579A - Terapia de combinacion para el tratamiento de la neoplasia. - Google Patents
Terapia de combinacion para el tratamiento de la neoplasia.Info
- Publication number
- MX2015011579A MX2015011579A MX2015011579A MX2015011579A MX2015011579A MX 2015011579 A MX2015011579 A MX 2015011579A MX 2015011579 A MX2015011579 A MX 2015011579A MX 2015011579 A MX2015011579 A MX 2015011579A MX 2015011579 A MX2015011579 A MX 2015011579A
- Authority
- MX
- Mexico
- Prior art keywords
- combination therapy
- receptor antagonist
- treatment
- neoplasia
- neoplasia treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención se refiere a un antagonista de los receptores con factor de crecimiento similar al de la insulina (IGF) para uso en el tratamiento de la neoplasia prostática que incluye la hiperplasia prostática benigna (HPB), cáncer de próstata, y particularmente CRPC, en el que el antagonista se utiliza en combinación con un antagonista de los receptores andrógenos. Una modalidad de la invención es aquella en donde el antagonista del receptor de los andrógenos es la enzalutamida.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13158228 | 2013-03-07 | ||
PCT/EP2014/054300 WO2014135611A1 (en) | 2013-03-07 | 2014-03-06 | Combination therapy for neoplasia treatment |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2015011579A true MX2015011579A (es) | 2015-12-09 |
MX367624B MX367624B (es) | 2019-08-29 |
Family
ID=47827067
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2015011579A MX367624B (es) | 2013-03-07 | 2014-03-06 | Uso combinado de un antagonista del receptor del factor de crecimiento similar a la insulina y un antagonista del receptor de andrógenos para tratar la neoplasia prostática. |
Country Status (16)
Country | Link |
---|---|
US (2) | US20140255413A1 (es) |
EP (1) | EP2964256B1 (es) |
JP (1) | JP6532828B2 (es) |
KR (1) | KR20150123859A (es) |
CN (1) | CN105007942A (es) |
AR (1) | AR095041A1 (es) |
AU (1) | AU2014224608B2 (es) |
BR (1) | BR112015020943A2 (es) |
CA (1) | CA2903645A1 (es) |
CL (1) | CL2015002455A1 (es) |
EA (1) | EA034884B1 (es) |
IL (1) | IL240599A0 (es) |
MX (1) | MX367624B (es) |
PH (1) | PH12015501852A1 (es) |
UY (1) | UY35371A (es) |
WO (1) | WO2014135611A1 (es) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI2376116T1 (sl) | 2008-12-12 | 2016-03-31 | Boehringer Ingelheim International Gmbh | Anti-IGF protitelesa |
US20140255413A1 (en) | 2013-03-07 | 2014-09-11 | Boehringer Ingelheim International Gmbh | Combination therapy for neoplasia treatment |
WO2015018421A1 (en) | 2013-08-07 | 2015-02-12 | Rigshospitalet Copenhagen University Hospital | Antibodies, compounds and derivatives thereof for use in the treatment of male infertility |
JP7372025B2 (ja) | 2014-09-17 | 2023-10-31 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | 固形がんおよび/またはその転移を処置する方法、そのための薬剤、ならびに固形がんおよび/またはその転移処置の臨床転帰を予測する方法 |
ES2897782T3 (es) * | 2014-09-17 | 2022-03-02 | Merck Patent Gmbh | Método de tratamiento de las enfermedades de la metástasis ósea, medicamentos para el tratamiento y método para predecir el resultado clínico del tratamiento de las enfermedades causadas por metástasis ósea |
US20180104332A1 (en) * | 2015-01-16 | 2018-04-19 | The University Of Liverpool | Insulin-like growth factor inhibitor and chemotherapeutic agent for use in cancer therapy |
EP3824908A1 (en) | 2015-04-10 | 2021-05-26 | Capsugel Belgium NV | Abiraterone acetate lipid formulations |
US20170088609A1 (en) | 2015-09-28 | 2017-03-30 | Boehringer Ingelheim International Gmbh | Anticancer combination therapy |
CN108114271B (zh) * | 2016-11-29 | 2021-07-02 | 中国科学院上海营养与健康研究所 | 含胰岛素样生长因子-2的药物组合物及其应用 |
CN111148534A (zh) | 2017-09-29 | 2020-05-12 | 勃林格殷格翰国际有限公司 | 抗igf和抗pd-1抗癌组合疗法 |
WO2019184952A1 (en) * | 2018-03-29 | 2019-10-03 | Hinova Pharmaceuticals Inc. | Deuterated imidazolidinedione compounds and their uses |
US20210332392A1 (en) * | 2020-04-24 | 2021-10-28 | Lawrence Livermore National Security, Llc | Compositions and methods of use thereof for scandium separation from rare earth containing material |
CN115721629B (zh) * | 2022-10-31 | 2024-02-20 | 西安交通大学 | 多西他赛与恩杂鲁胺联合用药pH响应型铁-铜磁性纳米载药系统及其制备和应用 |
Family Cites Families (94)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US4342566A (en) | 1980-02-22 | 1982-08-03 | Scripps Clinic & Research Foundation | Solid phase anti-C3 assay for detection of immune complexes |
ATE220101T1 (de) | 1983-04-25 | 2002-07-15 | Chiron Corp | Hybrid-dns-synthesis von reifen insulinähnlichen wachstumsfaktoren |
WO1985000831A1 (en) | 1983-08-10 | 1985-02-28 | Amgen | Microbial expression of insulin-like growth factor |
AU1232188A (en) | 1987-05-29 | 1988-12-01 | Mallinckrodt, Inc. | Novel pair of monoclonal antibodies to insulin-like growth factor i permits immunometric assay for igf-i |
DE68908175T2 (de) | 1988-05-27 | 1994-03-03 | Centocor Inc | Gefriergetrocknete formulierung für antikörperprodukte. |
JPH03501487A (ja) | 1988-06-30 | 1991-04-04 | シティ・オブ・ホープ | インシュリン模倣物およびインシュリンリセプター結合部位ペプチド |
CA2058041A1 (en) | 1990-06-27 | 1991-12-28 | Katsuichi Sakano | Anti-igf-ii monoclonal antibody |
WO1994029347A1 (en) | 1993-06-03 | 1994-12-22 | Therapeutic Antibodies Inc. | Antibody fragments in therapy |
WO1995025794A1 (fr) | 1994-03-23 | 1995-09-28 | Japan Clinical Laboratories | Anticorps monoclonal anti-igf-i |
US6685940B2 (en) | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
US6991790B1 (en) | 1997-06-13 | 2006-01-31 | Genentech, Inc. | Antibody formulation |
GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
ATE328903T1 (de) | 1997-11-27 | 2006-06-15 | Commw Scient Ind Res Org | Verfahren zur konstruktion von agonisten und antagonisten des igf-rezeptors (1-462) |
MXPA01010891A (es) | 1999-04-28 | 2002-11-07 | Univ Texas | Composiciones y metodos para el tratamiento contra el cancer mediante la inhibicion selectiva del factor de crecimiento endotelial vascular (vegf). |
UY27087A1 (es) | 2001-01-05 | 2002-06-20 | Pfizer | Anticuerpos contra el receptor del factor de crecimiento similar a insulina |
EP2706116A1 (en) | 2001-01-17 | 2014-03-12 | Emergent Product Development Seattle, LLC | Binding domain-immunoglobulin fusion proteins |
DK1399484T3 (da) | 2001-06-28 | 2010-11-08 | Domantis Ltd | Dobbelt-specifik ligand og anvendelse af denne |
US20050214857A1 (en) | 2001-12-11 | 2005-09-29 | Algonomics N.V. | Method for displaying loops from immunoglobulin domains in different contexts |
ES2427964T3 (es) | 2002-01-18 | 2013-11-05 | Pierre Fabre Medicament | Nuevos anticuerpos anti-IGF-IR y sus aplicaciones |
US7438911B2 (en) | 2002-04-30 | 2008-10-21 | Kyowa Hakko Kogyo Co., Ltd. | Antibody against human insulin-like growth factor |
JP2003310275A (ja) | 2002-04-30 | 2003-11-05 | Kyowa Hakko Kogyo Co Ltd | ヒトインスリン様成長因子に対する遺伝子組換え抗体 |
PL210412B1 (pl) | 2002-05-24 | 2012-01-31 | Schering Corp | Izolowane przeciwciało anty-IGFR lub jego fragment, kompozycja farmaceutyczna, zastosowanie, kwas nukleinowy, zrekombinowany wektor, komórka gospodarza, kompleks, polipeptyd i sposób jego wytwarzania |
US7538195B2 (en) | 2002-06-14 | 2009-05-26 | Immunogen Inc. | Anti-IGF-I receptor antibody |
US8034904B2 (en) | 2002-06-14 | 2011-10-11 | Immunogen Inc. | Anti-IGF-I receptor antibody |
EP1517921B1 (en) | 2002-06-28 | 2006-06-07 | Domantis Limited | Dual specific ligands with increased serum half-life |
US20030138430A1 (en) | 2002-09-20 | 2003-07-24 | Stimmel Julie Beth | Pharmaceutical comprising an agent that blocks the cell cycle and an antibody |
JP2006523090A (ja) | 2002-12-27 | 2006-10-12 | ドマンティス リミテッド | リガンドに、そしてリガンド受容体に特異的な二重特異性単一ドメイン抗体 |
KR20050109489A (ko) | 2003-02-13 | 2005-11-21 | 화이자 프로덕츠 인크. | 항-인슐린양 성장인자 i 수용체 항체의 용도 |
EP1603948A1 (en) | 2003-03-14 | 2005-12-14 | Pharmacia Corporation | Antibodies to igf-i receptor for the treatment of cancers |
ES2527871T3 (es) | 2003-05-01 | 2015-02-02 | Imclone Llc | Anticuerpos completamente humanos dirigidos contra el receptor del factor de crecimiento 1 similar a la insulina humana |
US7579157B2 (en) | 2003-07-10 | 2009-08-25 | Hoffmann-La Roche Inc. | Antibody selection method against IGF-IR |
WO2005018671A1 (ja) | 2003-08-21 | 2005-03-03 | Kyowa Hakko Kogyo Co., Ltd. | 癌転移阻害剤 |
US7498415B2 (en) | 2003-09-24 | 2009-03-03 | Kyowa Hakko Kogyo Co., Ltd. | Recombinant antibody against human insulin-like growth factor |
JPWO2005027970A1 (ja) | 2003-09-24 | 2007-11-15 | 協和醗酵工業株式会社 | 癌治療用医薬 |
WO2005058967A2 (en) | 2003-12-16 | 2005-06-30 | Pierre Fabre Medicament | Novel anti-insulin/igf-i hybrid receptor or anti-insulin/igf-i hybrid receptor and igf-ir antibodies and uses thereof |
WO2006008639A1 (en) * | 2004-07-16 | 2006-01-26 | Pfizer Products Inc. | Combination treatment for non-hematologic malignancies using an anti-igf-1r antibody |
MY146381A (en) | 2004-12-22 | 2012-08-15 | Amgen Inc | Compositions and methods relating relating to anti-igf-1 receptor antibodies |
EP1888647A2 (en) | 2005-05-24 | 2008-02-20 | MorphoSys AG | Generation and profiling of fully human hucal gold®-derived therapeutic antibodies specific for human cd38 |
FR2888850B1 (fr) | 2005-07-22 | 2013-01-11 | Pf Medicament | Nouveaux anticorps anti-igf-ir et leurs applications |
SG10201400973XA (en) | 2005-10-12 | 2014-08-28 | Morphosys Ag | Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human cd38 |
ES2385054T3 (es) | 2005-12-13 | 2012-07-17 | Medimmune Limited | Proteínas de unión específicas para factores de crecimiento de tipo insulina y usos de las mismas |
AP2008004569A0 (en) * | 2006-02-03 | 2008-08-31 | Imclone Systems Inc | IGR-IR antagonists as adjuvants for treatment of prostrate cancer |
EP1999149A4 (en) | 2006-03-28 | 2010-01-20 | Biogen Idec Inc | ANTI-IGF-1R ANTIBODIES AND USES THEREOF |
EP2010567A2 (en) | 2006-04-07 | 2009-01-07 | The Government of the United States of America as Represented by The Department of Health and Human Services | Antibody compositions and methods for treatment of neoplastic disease |
US20080014203A1 (en) | 2006-04-11 | 2008-01-17 | Silke Hansen | Antibodies against insulin-like growth factor I receptor and uses thereof |
KR101467136B1 (ko) | 2006-06-02 | 2014-12-01 | 화이자 프로덕츠 인코포레이티드 | 순환 종양 세포 분석 |
ATE537450T1 (de) | 2006-06-30 | 2011-12-15 | Schering Corp | Igfbp2-biomarker |
WO2008079324A1 (en) | 2006-12-21 | 2008-07-03 | Boston Biomedical Research Institute | Immunological modulation of insulin-like growth factor 1 for cancer prevention/treatment and prolonging longevity |
AR064464A1 (es) | 2006-12-22 | 2009-04-01 | Genentech Inc | Anticuerpos anti - receptor del factor de crecimiento insulinico |
GB0702888D0 (en) | 2007-02-14 | 2007-03-28 | Glaxo Group Ltd | Novel Antibodies |
EP2129397B1 (en) | 2007-03-02 | 2018-10-31 | Amgen, Inc. | Methods and compositions for treating tumor diseases |
WO2008115470A2 (en) | 2007-03-16 | 2008-09-25 | East Carolina University | Hox-gene expression as a biomarker for igf-1r therapeutics |
KR20090113340A (ko) | 2007-03-22 | 2009-10-29 | 임클론 엘엘씨 | 안정한 항체 제제 |
EP2559771A3 (en) | 2007-05-17 | 2013-06-12 | Bristol-Myers Squibb Company | Biomarkers and methods for determining sensitivity to insulin growth factor-1 receptor modulators |
WO2008144720A2 (en) | 2007-05-21 | 2008-11-27 | University Of Washington | Inhibitors of igf-1r signaling for the treatment of respiratory disorders |
WO2008152422A2 (en) | 2007-06-12 | 2008-12-18 | Astrazeneca Ab | Binding proteins specific for insulin-like growth factors and uses thereof-909 |
PE20090368A1 (es) | 2007-06-19 | 2009-04-28 | Boehringer Ingelheim Int | Anticuerpos anti-igf |
WO2009006336A1 (en) | 2007-06-28 | 2009-01-08 | Sylgen Laboratories, Inc. | Compositions and methods for inhibiting angiogenesis and tumorigenesis |
WO2009005673A1 (en) | 2007-06-28 | 2009-01-08 | Schering Corporation | Anti-igf1r |
JP2010535710A (ja) | 2007-07-31 | 2010-11-25 | メルク・シャープ・エンド・ドーム・コーポレイション | 細胞増殖性疾患の検出及び診断に有用なigf−1r特異抗体 |
CA2694055A1 (en) | 2007-08-01 | 2009-02-05 | Glaxo Group Limited | Novel antibodies |
EP2183275B1 (en) | 2007-08-03 | 2014-10-29 | Affibody AB | Igf-1r binding polypeptides and their use |
EP2952588A1 (en) | 2007-08-06 | 2015-12-09 | Orion Genomics, LLC | Single nucleotide polymorphism in igf2 for determining the allele-specific expression of the igf2 gene |
WO2009032782A2 (en) | 2007-08-28 | 2009-03-12 | Biogen Idec Ma Inc. | Compositions that bind multiple epitopes of igf-1r |
CN101842117A (zh) | 2007-08-28 | 2010-09-22 | 比奥根艾迪克Ma公司 | 抗igf-1r抗体及其用途 |
EP2193211A4 (en) | 2007-09-19 | 2010-12-08 | Univ Boston | IDENTIFICATION OF NEW PATHWAYS FOR THE DEVELOPMENT OF MEDICINES FOR THE TREATMENT OF LUNG DISEASES |
EP2201378A2 (en) | 2007-10-03 | 2010-06-30 | OSI Pharmaceuticals, Inc. | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
US8048621B2 (en) | 2007-10-03 | 2011-11-01 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
TWI580694B (zh) * | 2007-11-30 | 2017-05-01 | 建南德克公司 | 抗-vegf抗體 |
MX2010006854A (es) | 2007-12-18 | 2010-09-09 | Schering Corp | Biomarcadores para sensibilidad a terapia anti-receptor-1 del factor de crecimiento tipo insulina. |
US20090258365A1 (en) | 2008-03-25 | 2009-10-15 | Terstappen Leon W M M | METHOD FOR DETECTING IGF1R/Chr 15 in CIRCULATING TUMOR CELLS USING FISH |
CN102065895A (zh) | 2008-04-11 | 2011-05-18 | 比奥根艾迪克Ma公司 | 抗-igf-1r抗体和其它化合物的治疗联合 |
CA2722992A1 (en) | 2008-05-05 | 2009-11-12 | Schering Corporation | Sequential administration of chemotherapeutic agents for treatment of cancer |
WO2009137758A2 (en) | 2008-05-09 | 2009-11-12 | Dyax Corp. | Igf-ii/gf-iie binding proteins |
KR20110016959A (ko) | 2008-06-03 | 2011-02-18 | 아보트 러보러터리즈 | 이원 가변 도메인 면역글로불린 및 이의 용도 |
CN102224239A (zh) | 2008-09-26 | 2011-10-19 | 先灵公司 | 高效价抗体生产 |
MX2011003133A (es) | 2008-09-26 | 2011-04-21 | Roche Glycart Ag | Anticuerpos biespecificos anti-egfr/anti-igf-1r. |
CA2740440A1 (en) | 2008-10-14 | 2010-04-22 | Dyax Corp. | Use of igf-ii/igf-iie binding proteins for the treatment and prevention of systemic sclerosis-associated pulmonary fibrosis |
JP2012506238A (ja) | 2008-10-20 | 2012-03-15 | ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド,ア ボディー コーポレイト | インスリン様増殖因子−1受容体キナーゼ阻害剤に対する抗がん反応を予測する生物学的マーカー |
CN102232087A (zh) | 2008-11-10 | 2011-11-02 | 诺瓦提斯公司 | 修饰的人igf-1/e肽的抗体 |
EP2350649A4 (en) | 2008-11-28 | 2012-11-14 | Abbott Lab | STABLE ANTIBODY COMPOSITIONS AND METHODS FOR STABILIZING THE SAME |
SI2376116T1 (sl) | 2008-12-12 | 2016-03-31 | Boehringer Ingelheim International Gmbh | Anti-IGF protitelesa |
WO2010069858A1 (en) | 2008-12-19 | 2010-06-24 | F. Hoffmann-La Roche Ag | Pharmaceutical composition |
EP2381774A4 (en) | 2008-12-23 | 2012-07-18 | Salk Inst For Biological Studi | METHOD OF TREATING NEURODEGENERATIVE DISEASE |
JP2012524087A (ja) | 2009-04-16 | 2012-10-11 | メルク・シャープ・エンド・ドーム・コーポレイション | 抗egfr物質とigf−1r特異的インヒビターとを使用する組合せ療法 |
WO2011057064A1 (en) * | 2009-11-05 | 2011-05-12 | Brian Long | Igf1r inhibitor based treatment of prostate cancer |
WO2013000148A1 (en) * | 2011-06-30 | 2013-01-03 | Renesas Mobile Corporation | Method and apparatus for improved wireless sensor network interactions |
WO2013148568A1 (en) * | 2012-03-30 | 2013-10-03 | Merck Sharp & Dohme Corp. | Igf1 biomarker for igf1r inhibitor therapy |
WO2013169611A1 (en) | 2012-05-09 | 2013-11-14 | Merck Sharp & Dohme Corp. | Compositions and methods for treating breast cancer |
JOP20200097A1 (ar) * | 2013-01-15 | 2017-06-16 | Aragon Pharmaceuticals Inc | معدل مستقبل أندروجين واستخداماته |
US20140255413A1 (en) | 2013-03-07 | 2014-09-11 | Boehringer Ingelheim International Gmbh | Combination therapy for neoplasia treatment |
RS59649B1 (sr) | 2014-01-24 | 2020-01-31 | Boehringer Ingelheim Int | Lečenje raka korišćenjem receptora antagoniste faktora rasta sličan insulinu (igf) u kombinaciji sa eksemestanom i everolimusom |
US20170088609A1 (en) | 2015-09-28 | 2017-03-30 | Boehringer Ingelheim International Gmbh | Anticancer combination therapy |
-
2014
- 2014-03-04 US US14/196,231 patent/US20140255413A1/en not_active Abandoned
- 2014-03-06 CN CN201480010868.8A patent/CN105007942A/zh active Pending
- 2014-03-06 CA CA2903645A patent/CA2903645A1/en not_active Abandoned
- 2014-03-06 MX MX2015011579A patent/MX367624B/es active IP Right Grant
- 2014-03-06 JP JP2015560682A patent/JP6532828B2/ja not_active Expired - Fee Related
- 2014-03-06 BR BR112015020943A patent/BR112015020943A2/pt not_active IP Right Cessation
- 2014-03-06 AU AU2014224608A patent/AU2014224608B2/en not_active Ceased
- 2014-03-06 EA EA201500906A patent/EA034884B1/ru not_active IP Right Cessation
- 2014-03-06 WO PCT/EP2014/054300 patent/WO2014135611A1/en active Application Filing
- 2014-03-06 KR KR1020157026215A patent/KR20150123859A/ko not_active Application Discontinuation
- 2014-03-06 EP EP14709911.3A patent/EP2964256B1/en active Active
- 2014-03-06 AR ARP140100739A patent/AR095041A1/es unknown
- 2014-03-07 UY UY0001035371A patent/UY35371A/es unknown
-
2015
- 2015-08-17 IL IL240599A patent/IL240599A0/en unknown
- 2015-08-24 PH PH12015501852A patent/PH12015501852A1/en unknown
- 2015-09-02 CL CL2015002455A patent/CL2015002455A1/es unknown
- 2015-11-19 US US14/946,067 patent/US10377828B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
MX367624B (es) | 2019-08-29 |
PH12015501852B1 (en) | 2016-01-18 |
EA034884B1 (ru) | 2020-04-01 |
EP2964256A1 (en) | 2016-01-13 |
CA2903645A1 (en) | 2014-09-12 |
JP2016511265A (ja) | 2016-04-14 |
WO2014135611A1 (en) | 2014-09-12 |
AU2014224608B2 (en) | 2018-08-09 |
BR112015020943A2 (pt) | 2017-10-10 |
EP2964256B1 (en) | 2020-11-11 |
UY35371A (es) | 2014-09-30 |
NZ711210A (en) | 2020-11-27 |
AU2014224608A1 (en) | 2015-09-10 |
EA201500906A1 (ru) | 2016-03-31 |
KR20150123859A (ko) | 2015-11-04 |
US20140255413A1 (en) | 2014-09-11 |
US10377828B2 (en) | 2019-08-13 |
AR095041A1 (es) | 2015-09-16 |
JP6532828B2 (ja) | 2019-06-19 |
US20160199488A1 (en) | 2016-07-14 |
CN105007942A (zh) | 2015-10-28 |
PH12015501852A1 (en) | 2016-01-18 |
CL2015002455A1 (es) | 2016-05-27 |
IL240599A0 (en) | 2015-09-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2015011579A (es) | Terapia de combinacion para el tratamiento de la neoplasia. | |
PH12018502570A1 (en) | Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer | |
MX2018006831A (es) | Metodos de tratamiento de neoplasias malignas. | |
EP3618914A4 (en) | IMPLANTABLE DEVICES AND TREATMENT METHODS FOR BENIGN PROSTATE HYPERPLASIA (BPH) AND ASSOCIATED LOWER URINARY TRACT SYMPTOMS (LUTS) | |
MX2016001901A (es) | Biomarcadores para tratamiento de trastornos neoplasicos usando terapias dirigidas con andrógeno. | |
JO3606B1 (ar) | معدل مستقبل الأندروجين في توليفة مع أسيتات أبراتيرون وبريدنيزون لعلاج سرطان البروستاتا | |
TW201613647A (en) | Compounds and compositions for treating HER2 positive tumors | |
MX2016007885A (es) | Metodos de tratamiento de cancer usando antagonistas de union del eje de pd-1 y un anticuerpo anti-cd20. | |
MX2016004678A (es) | Composiciones para el tratamiento del cancer. | |
EP3061459A4 (en) | Composition for treating and preventing benign prostatic hyperplasia | |
MX2016000510A (es) | Metodos para tratar cancer utilizando antagonistas de union al eje pd-1 e inhibidores de tigit. | |
WO2012018404A3 (en) | Use of her3 binding agents in prostate treatment | |
JP2014503537A5 (es) | ||
PH12015502855A1 (en) | Peptides and petidomimetics in combination uses and treatments for cancer patient subpopulations | |
PH12015502342B1 (en) | Combination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer | |
CL2015003595A1 (es) | Inhibidores/antiandrógenos novedosos de cyp17 | |
MX2017006076A (es) | Dianhidrogalactitol junto con radiacion, para tratar carcinoma de pulmón de celulas no pequeñas y glioblastoma multiforme. | |
MX2016009515A (es) | Metodos para utilizar anticuerpos anti-steap1 e inmunoconjugados. | |
MX2010004259A (es) | Tratamientos antitumorales mejorados. | |
NZ742470A (en) | Combination therapy for cancer | |
PH12018502571A1 (en) | Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer | |
MX2019011118A (es) | Uso de oleorresina de copaifera en patologias de la prostata. | |
GB201612794D0 (en) | Therapeutic use of diethanololeamide in prostate cancer treatment | |
CL2009001982A1 (es) | Compuestos derivados de pirrolidin-1-il benzonitrilo; y su uso en el tratamiento del cancer de prostata hormono dependiente mediado por el antagonismo del receptor de androgenos. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |